13 completed, 1 terminated. 11 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow TER 286: new trials by email Literature Review of TER 286 trials Research Report on TER 286
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma Canfosfamide HCl for injection - Mantle Cell Lymphoma, B Cell Lymphoma | Phase 2 | Completed | Telik | 14 | 2010-06-01 | 2013-03-15 |
| Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer Telcyta, Liposomal Doxorubicin - Ovarian Neoplasms | Phase 3 | Terminated | Telik | 244 | 2006-05-01 | 2013-11-27 |
| TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer TLK286 in Combination with Carboplatin, Doxorubicin HCl Liposome Injection - Ovarian Neoplasms | Phase 3 | Completed | Telik | 244 | 2004-12-01 | 2012-05-31 |
| Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer TLK286, carboplatin, paclitaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Telik | 100 | 2004-08-01 | 2012-05-31 |
| TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) TLK286, cisplatin - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Telik | 50 | 2004-02-01 | 2011-07-25 |
| TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer TLK286 - Ovarian Neoplasms | Phase 1 / Phase 2 | Completed | Telik | 28 | 2003-02-01 | 2011-07-25 |
| TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer TLK286 - Ovarian Neoplasms | Phase 1 / Phase 2 | Completed | Telik | 28 | 2003-01-01 | 2011-07-25 |
| Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer TLK286 in combination with docetaxel - Carcinoma, Non-small-cell Lung | Phase 1 / Phase 2 | Completed | Telik | 28 | 2002-10-01 | 2011-07-25 |
| Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer TLK286 - Carcinoma, Non-small-cell Lung | Phase 2 | Completed | Telik | 40 | 2002-07-01 | 2011-07-25 |
| Phase 2 Study of TLK286 in Metastatic Breast Cancer TLK286 - Breast Neoplasms | Phase 2 | Completed | Telik | 60 | 2002-04-01 | 2011-07-25 |
| TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer canfosfamide hydrochloride - Lung Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2002-01-01 | 2013-06-26 | |
| Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer TLK286 - Ovarian Neoplasms | Phase 2 | Completed | Telik | 40 | 2001-06-01 | 2011-07-25 |
| TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer canfosfamide hydrochloride - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-05-01 | 2013-06-26 | |
| Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa) - Non Small Cell Lung Carcinoma | Phase 3 | Completed | Telik | 520 | 2008-01-15 |
Carcinoma, Non-Small-Cell Lung (6) · Ovarian Neoplasms (6) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
Telik (12) · Memorial Sloan Kettering Cancer Center (2)
United States (14) · Brazil (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · Chile (1) · Germany (1) · Italy (1)
David R. Spriggs, MD (1) · Gail L. Brown, MD, MBA (1) · Joseph Bertino, MD (1) · Mark G. Kris, MD (1)